Finanças

Notícias Discussões Sinais técnicos Previsão Sazonais Opções

Receita antes de impostos de Amylyx Pharmaceuticals, Inc..

Dados anuais

2020

2021

2022

2023

2024

TTM

‪‪−330,00 M‬‬

‪‪−220,00 M‬‬

‪‪−110,00 M‬‬

‪0,00‬

‪‪110,00 M‬‬

Período

Valor

Variação

Variação %

TTM

‪‪−302,14 M‬‬

‪0,00‬

‪0,00‬%

2024

‪‪−302,14 M‬‬

‪‪−356,43 M‬‬

‪−656,45‬%

2023

‪‪54,30 M‬‬

+‪‪251,90 M‬‬

—

2022

‪‪−197,60 M‬‬

‪‪−109,67 M‬‬

‪−124,72‬%

2021

‪‪−87,93 M‬‬

‪‪−45,65 M‬‬

‪−107,97‬%

2020

‪‪−42,28 M‬‬

‪‪−28,56 M‬‬

‪−208,25‬%

Dados trimestrais

Q1 '21

Q2 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−120,00 M‬‬

‪‪−80,00 M‬‬

‪‪−40,00 M‬‬

‪0,00‬

‪‪40,00 M‬‬

Período

Valor

Variação

Variação %

Q4 '24

‪‪−38,18 M‬‬

+‪‪34,52 M‬‬

+‪47,48‬%

Q3 '24

‪‪−72,70 M‬‬

‪‪−4,00 K‬‬

‪−0,01‬%

Q2 '24

‪‪−72,70 M‬‬

+‪‪45,85 M‬‬

+‪38,68‬%

Q1 '24

‪‪−118,55 M‬‬

‪‪−125,03 M‬‬

‪‪−1,93 K‬‬%

Q4 '23

‪‪6,48 M‬‬

‪‪−15,94 M‬‬

‪−71,10‬%

Q3 '23

‪‪22,41 M‬‬

‪‪−1,60 M‬‬

‪−6,65‬%

Q2 '23

‪‪24,01 M‬‬

+‪‪22,60 M‬‬

+‪‪1,61 K‬‬%

Q1 '23

‪‪1,40 M‬‬

+‪‪43,53 M‬‬

—

Q4 '22

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q2 '21

Q1 '21